Admired & Respected

Innogene is globally well respected and renowned for its culture of innovation and expertise within the biopharmaceutical industry

We Know Asia

Innogene Kalbiotech is firmly rooted in Asia, leveraging our strength, experience and global reputation as a leader. We’ve built international strategic marketing and distribution networks across emerging markets

Innogene Kalbiotech at a Glance

A biotechnology company focusing on novel biologics, biosimilars and novel diagnostics. A part of Kalbe Group and a subsidiary company of PT Kalbe Genexine Biologics (KGbio).

Find Out More

Our Capabilities

Novel Diagnostics

One of our precision oncology test Mammaprint, was the first FDA cleared IVDMIA breast cancer recurrence assay.

Therapeutics

We have various drugs in key therapeutics areas such as biosimilars, novel cancer drugs and diagnostics, which are commercialized in most ASEAN countries.

Other Services

We welcome collaborations in clinical development with companies which have strong science-based pipeline. We and our sister companies also provide laboratory services such as BA (Bioavailability) and BE (Bioequivalence) studies, CMO for biologics, and diagnostic services including biomarker.

Zhao Yanqing

President Director of Kexing Biopharm Co. Ltd

As a leading pharmaceutical enterprise in Southeast Asia, Innogene Kalbiotech (IGK) is one of our most important business partner in Southeast Asia, maintained a mutually beneficial relationship with us for about 20 years. IGK is a good partner with honest and practical style, I believe that we will continue to go hand in hand and expand the scope of cooperation in the future to make a contribution to Indonesia and the whole human health with the support of the friendship bridge between China and Indonesia.

Susheel Umesh

Chief Commercial Officer, Emerging Markets, Biocon Biologics

We are glad that through Kalbe we are able to address unmet needs of breast cancer patients through our affordable Trastuzumab which is a leading brand in its segment in Indonesia. We look forward to strengthening this synergistic partnership and expanding our product portfolio to enhance access to patients, in Indonesia.